Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe.
Vrdoljak E, Gligorov J, Wierinck L, Conte P, De Grève J, Meunier F, Palmieri C, Travado L, Walker A, Wiseman T, Wuerstlein R, Alba E, Biurrún C, D'Antona R, Sola-Morales O, Ubaysi C, Ventura R, Cardoso F. Vrdoljak E, et al. Breast. 2021 Feb;55:79-90. doi: 10.1016/j.breast.2020.12.005. Epub 2020 Dec 13. Breast. 2021. PMID: 33360479 Free PMC article. Review.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. von Minckwitz G, et al. Among authors: vrdoljak e. Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273342 Clinical Trial.
The European Code of Cancer Practice.
Lawler M, Oliver K, Gijssels S, Aapro M, Abolina A, Albreht T, Erdem S, Geissler J, Jassem J, Karjalainen S, La Vecchia C, Lievens Y, Meunier F, Morrissey M, Naredi P, Oberst S, Poortmans P, Price R, Sullivan R, Velikova G, Vrdoljak E, Wilking N, Yared W, Selby P. Lawler M, et al. Among authors: vrdoljak e. J Cancer Policy. 2021 Jun;28:100282. doi: 10.1016/j.jcpo.2021.100282. Epub 2021 Apr 19. J Cancer Policy. 2021. PMID: 35559911 Free article. Review.
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission.
Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, La Vecchia C, Allemani C, Lievens Y, Naredi P, Cufer T, Aggarwal A, Aapro M, Apostolidis K, Baird AM, Cardoso F, Charalambous A, Coleman MP, Costa A, Crul M, Dégi CL, Di Nicolantonio F, Erdem S, Geanta M, Geissler J, Jassem J, Jagielska B, Jonsson B, Kelly D, Kelm O, Kolarova T, Kutluk T, Lewison G, Meunier F, Pelouchova J, Philip T, Price R, Rau B, Rubio IT, Selby P, Južnič Sotlar M, Spurrier-Bernard G, van Hoeve JC, Vrdoljak E, Westerhuis W, Wojciechowska U, Sullivan R. Lawler M, et al. Among authors: vrdoljak e. Lancet Oncol. 2023 Jan;24(1):e11-e56. doi: 10.1016/S1470-2045(22)00540-X. Epub 2022 Nov 16. Lancet Oncol. 2023. PMID: 36400101 Free article. Review.
Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O, Cufer T, Dixon JM, Maass N, Marchetti P, Pagani O, Pronzato P, Semiglazov V, Spano JP, Vrdoljak E, Wildiers H. Ortmann O, et al. Among authors: vrdoljak e. Breast. 2009 Feb;18(1):2-7. doi: 10.1016/j.breast.2008.10.002. Epub 2008 Nov 26. Breast. 2009. PMID: 19036588 Free article. Review.
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Sparano JA, et al. Among authors: vrdoljak e. J Clin Oncol. 2010 Jul 10;28(20):3256-63. doi: 10.1200/JCO.2009.24.4244. Epub 2010 Jun 7. J Clin Oncol. 2010. PMID: 20530276 Free PMC article. Clinical Trial.
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Vrdoljak E, et al. Ann Oncol. 2016 Nov;27(11):2046-2052. doi: 10.1093/annonc/mdw316. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502725 Free article. Clinical Trial.
Biosimilars in the Treatment of Breast Cancer.
Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E. Balic M, et al. Among authors: vrdoljak e. Breast Care (Basel). 2017 Jul;12(3):192-194. doi: 10.1159/000477926. Epub 2017 Jun 13. Breast Care (Basel). 2017. PMID: 28785188 Free PMC article. No abstract available.
113 results